Last updated Friday, September 30, 2016 6:07 pm GMT+8

Friday September 23, 2016
10:57 AM GMT+8

Advertisement

More stories

Aedes aegypti mosquitoes are seen inside Oxitec laboratory in Campinas, Brazil, February 2, 2016. — Reuters picAedes aegypti mosquitoes are seen inside Oxitec laboratory in Campinas, Brazil, February 2, 2016. — Reuters picWASHINGTON, Sept 23 — A pair of experimental vaccines being developed by the US National Institutes of Health protected monkeys against Zika virus infection after two doses, researchers said yesterday.

One of the vaccines, known as VRC5288, has already begun early trials in humans to test safety and efficacy, according to a study published in Science.

A phase 2 trial in Zika-endemic countries could begin next year, officials said.

The second vaccine (VRC5283) is awaiting a Phase 1 clinical trial start date.

The research involved vaccinating rhesus macaques using “the two different experimental Zika DNA vaccines in different doses,” said the NIH in a statement.

Two doses were “highly effective” at protecting macaques exposed to an infectious dose of Zika virus. 

Experts say it will be years before a vaccine is developed to prevent infection from Zika, which is particularly dangerous to pregnant women because it can cause brain defects in the foetus. — AFP

MORE ON MMOTV

Advertisement

MMO Instagram

Tweets by @themmailonline